Minerva Neurosciences (NASDAQ:NERV) was downgraded by equities research analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Monday, ValuEngine reports.
NERV has been the topic of a number of other reports. William Blair assumed coverage on Minerva Neurosciences in a report on Wednesday, September 18th. They issued an “outperform” rating and a $26.00 price target on the stock. Zacks Investment Research upgraded Minerva Neurosciences from a “hold” rating to a “strong-buy” rating and set a $7.75 price target on the stock in a report on Friday, August 9th. Chardan Capital assumed coverage on Minerva Neurosciences in a report on Wednesday, September 25th. They issued a “buy” rating and a $17.00 price target on the stock. Finally, BidaskClub upgraded Minerva Neurosciences from a “strong sell” rating to a “sell” rating in a report on Friday, August 23rd. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $18.19.
Shares of Minerva Neurosciences stock traded down $0.43 during trading on Monday, reaching $7.75. The stock had a trading volume of 379,179 shares, compared to its average volume of 371,508. The company has a market capitalization of $320.98 million, a price-to-earnings ratio of -6.01 and a beta of 1.54. The stock has a fifty day moving average price of $7.48 and a two-hundred day moving average price of $6.78. Minerva Neurosciences has a 52 week low of $4.07 and a 52 week high of $12.80.
Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.10. On average, analysts anticipate that Minerva Neurosciences will post -1.48 earnings per share for the current fiscal year.
Several large investors have recently added to or reduced their stakes in NERV. BNP Paribas Arbitrage SA increased its position in shares of Minerva Neurosciences by 63,940.0% in the first quarter. BNP Paribas Arbitrage SA now owns 6,404 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 6,394 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new stake in shares of Minerva Neurosciences in the second quarter valued at about $54,000. Parametric Portfolio Associates LLC acquired a new stake in shares of Minerva Neurosciences in the second quarter valued at about $56,000. Quantitative Systematic Strategies LLC acquired a new stake in shares of Minerva Neurosciences in the second quarter valued at about $62,000. Finally, Jane Street Group LLC acquired a new stake in shares of Minerva Neurosciences in the second quarter valued at about $88,000. 74.24% of the stock is currently owned by institutional investors and hedge funds.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.
Further Reading: Hedge Funds Explained
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.